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It has been previously suggested that human thioredoxin reductase activity is regulated by calcium. However, the activity of a purified form of 
human placental thioredoxin reductase was found to not be affected by mM concentrations of calcium, well above intra- and extracellular 
physiological levels. Furthermore, the suggestion that an E~F hand is present in Escherichia coli thioredoxin reductase is strongly contested. These 
current results uggest that human thioredoxin reductase is not regulated by calcium. 
Flavoenzyme; Human; Calcium; Redox 
1. INTRODUCTION 
The proteins thioredoxin (Trx) and thioredoxin re- 
ductase (TR) comprise a ubiquitous redox system pres- 
ent in both prokaryotic and eukaryotic organisms (for 
a review, see [1]). Schallreuter and colleagues have re- 
ported that purified human TR is regulated in an allo- 
steric manner by Ca 2+ at physiological levels [24]. On 
this basis, Ca 2+ fluxes between tumor and surrounding 
epidermis have been suggested to account for differ- 
ences in TR activity between primary human melano- 
mas and their surrounding normal skin [5]. 
The issue of Ca 2+ regulation of TR activity is an 
important biochemical point to clarify. The Trx/TR 
redox system has been recognized to be important in 
regulating ene expression through modulation of tran- 
scription factor activity [6,7]. Furthermore, human Trx 
has been shown to be identical to the human adult T-cell 
leukemia-derived factor (ADF) [8,9], an autocrine 
growth factor produced by leukemic cells [10], and a 
recombinant form of human Trx has been shown to 
stimulate cellular proliferation in a redox specific man- 
ner [11]. TR is found on the surface of some cancer cells 
and could be responsible for the reductive activation of 
extracellular Trx [5]. Thus, Ca 2+ regulation of TR activ- 
ity, if it occurs, could have significant consequences for 
the biological effects of the Trx and TR redox system. 
We have recently reported the purification and char- 
acterization of human TR from placental tissue [12]. In 
contrast o the earlier eports, we have now determined 
that human TR activity is not affected by Ca 2+ up to 
mM levels. 
*Corresponding author. 
2. RESULTS 
TR was purified from human placental tissue and was 
shown to have the same isoelectric point, size, and Km 
values as those reported for rat liver TR [12,13]. TR 
activity was measured by two separate spectrophoto- 
metric assays [13]. The first assay monitored the reduc- 
tion of DTNB by TR as the change in absorbance at 412 
nm over time. The second assay measured the oxidation 
of NADPH by the change in absorbance at 340 nm 
during the linked reduction of insulin by TR recombi- 
nant human Trx [9,12]. Incubation of human TR with 
increasing concentrations of Ca 2+ up to 5 mM for 10 
min had no effect on either the rate of DTNB reduction 
or NADPH oxidation (Fig. 1). Furthermore, incuba- 
tion of human TR in medium without added Ca 2+ and 
250/tM EGTA had no effect on the rate of DTNB 
reduction compared to medium with mM concentra- 
tions of Ca 2+ (data not shown). 
A Ca 2+ binding EF-hand domain was speculated to 
be present in both E. coli TR and human TR by 
Schallreuter and Wood [3,4], based on their identifica- 
tion of a potential domain in E. coli TR with suggested 
homology to one of the four EF-hands in calmodulin. 
However, upon examination of the speculated omain, 
it is evident that a critical aspartic acid and glycine 
residue are missing at positions 3 and 6, and 2 residues 
at the end of the 12 residue E-F  hand loop domain 
required for chelation of the Ca 2+ ion are absent [14]. 
The tertiary structure of E. coli TR has been solved 
recently by X-ray crystallography [15]. The authors of 
this study did not identify the presence of an EF-hand 
in E. coli TR. Using an updated version of the same 
computer sequence analysis ystem used by Schallreuter 
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Fig. 1. Effect of Ca 2+ on human placental thioredoxin reductase activ- 
ity. Human thioredoxin reductase was purified from placental tissue 
as previously described (Oblong et al. [12]). Aliquots of thioredoxin 
reductase were incubated with increasing concentrations of Ca 2+ for 
10 min and then assayed ineither the DTNB reduction assay (left axis, 
closed circles) or insulin reduction assay (right axis, open circles) as 
previously described [12,13]. 
Trx as a substrate was not reported and the flavin bind- 
ing properties of  the enzyme appear atypical for flavo- 
enzyme reductases. The reported absorbance spectra 
for the melanoma TR had an absorbance maximum at 
450 nm [3]. This is the absorbance maximum of  free 
FAD [16]. The characteristic absorbance maxima of the 
FAD group in flavoprotein reductases occurs at 464 nm 
[17,18], as occurs in human placental and rat liver TR  
[12,13]. We have found, however, that irreversible de- 
naturation of  human placental TR  results in a shifting 
of  the absorbance maxima from 464 nm to 450 nm [12]. 
Since we found no Ca 2+ effect on the activity of  puri- 
fied human TR from placenta and could find no E -F  
hand motif  in the sequence of E. coli TR, as claimed, 
it seems highly unlikely that TR is a Ca2+-regulated 
enzyme. We suggest hat the ambiguity in the literature 
concerning the Ca 2+ regulation of  TR activity may be 
due to the purification by Schallreuter and Wood of 
either an isoform of TR that is less stable than placental 
TR, or to another reductase. 
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and Wood [3] we found there is no EF-hand domain 
present in E. coli TR ( 'PROSITE '  program in the 1991 
PC/GENE software package (Version 6.6) from Intelli- 
genetics, Inc., Mountain View, CA). This version of  the 
software package includes identification of  different 
families of  calcium-binding proteins from all published 
sequences to date. The domain in the E. coli enzyme 
suggested by Schallreuter and Wood to be homologous 
to the EF-hand domain in calmodulin did not reveal the 
presence of  a Ca2+-binding site when analyzed by 
'PROSITE' .  
3. D ISCUSSION 
The question of  whether Ca 2+ can regulate human TR 
activity is of  considerable biological significance given 
the reported growth stimulatory activity of  Trx for both 
normal and cancer cells [10,11]. Growth stimulation by 
Trx requires the redox activity of  Trx [11] and Trx could 
be reduced by TR  that is present on the outside of  some 
cancer cells [5]. Thus, alterations in extracellular Ca R+ 
levels might affect TR  activity and, indirectly, the 
growth stimulation by Trx. Schallreuter and Wood [3] 
have attempted to explain differences in TR  activity of  
melanoma nd normal cells by differences in tissue Ca 2+ 
concentrations. However, in our studies we could find 
no evidence to substantiate the claim that human TR is 
a Ca 2+ regulated flavoenzyme by either ¢tM or mM 
levels of  the cation. 
The work by Schallreuter and colleagues used a par- 
tially purified preparation of  TR  from human mela- 
noma cells [2,3]. The specificity of  this preparation for 
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